Occurrence of neutrophil dysplasia in the course of severe nephrotic syndrome in a 12-year-old boy on immunosuppressive therapy: Questions by unknown
CLINICAL QUIZ
Occurrence of neutrophil dysplasia in the course of severe
nephrotic syndrome in a 12-year-old boy on immunosuppressive
therapy: Questions
Lidia Hyla-Klekot1 & Paweł Rajwa2 & Andrzej Paradysz2 & Piotr Bryniarski2
Received: 12 May 2016 /Accepted: 16 May 2016 /Published online: 30 June 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Keywords Nephrotic syndrome . Immunosupressive therapy
Case report
A 12-year-old boy has been treated since he was 9 months old
due to severe, recurring, steroid-dependent nephrotic syndrome
caused by focal segmental glomerulosclerosis (FSGS). He has
been permanently receiving immunosuppressive medications
(Table 1).
The nephrotic syndrome occurring in the patient can be
characterized as follows:
1. The disease developed prior to the boy’s first birthday.
2. Results of genetic tests were negative for mutations of the
nephrin, podocin and WT1 genes.
3. He has suffered from frequent relapses of nephrotic
syndrome.
4. There is evident high-dose steroid dependency that co-
exists with cyclosporine A (CsA) toxicity.
5. There is a transient, positive reaction to treatment with
alkylating agents.
A renal biopsy performed when the patient was 3 years
old revealed a minimal change disease. In 2013, at the age
of 10 years, due to an increase in the frequency of re-
lapses the patient was started on combination therapy with
CsA and mycophenolate mofetil (MMF). This combina-
tion therapy sustained remission for a few months, with-
out any observable clinical side effects or laboratory-
proven disorders. Beginning in January 2014 an increase
in the frequency of recurrence of nephrotic-range protein-
uria was observed, which led to the decision to add meth-
ylprednisolone pulses to the therapeutic regimen. A diag-
nostic biopsy revealed pathological features of FSGS and
CsA nephrotoxity. Based on these histopathological find-
ings, the decision was made to discontinue CsA therapy
and to administer rituximab (Rtx) with subsequent gradual
MMF withdrawal. In August 2014, Rtx was administered
in two doses of 375 mg/m2 with 1 week between doses.
Table 1 Course of the disease and treatment between 2004 and 2014
Years of
treatment
Course of the disease Treatment
2004 Manifestation of the disease,
steroid-dependency
GCs, CsA
2004-2006 Relapse of nephrotic syndrome
during an infection
CsA, GCs
2008-2009 Two relapses of nephrotic
syndrome
GCs, CsA, INN
2010-2011 Remission of nephrotic syndrome GCs, CsA
2012-2013 Frequent relapses of nephrotic
syndrome
GCs, CsA, MMF




GCs, Glucocorticosteroids; CsA, cyclosporine; INN, cyclophosphamide;
MMF, mycophenolate mofetil; Rtx, rituximab
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During the period of Rtx administration, the patient was
in clinical remission, with proteinuria of <200 mg/24 h, a
glomerular filtration rate of 80 ml/min/1.73m2 and serum
total protein of 6.4 g/dl; no signs of infection were found.
Directly after the Rtx treatment, the patient received
MMF 2× 1000 mg (650 mg/m2) and prednisone (5 mg/
day). Flow cytometry at 3 months after the final dose of
Rtx revealed total depletion of CD20 B-lymphocytes.
Complete blood count showed leukopenia of 2400 cells/
cmm with a concomitant increase (in percentage) of im-
mature granulocytes in the peripheral blood (myelocytes
10 %, metamyelocytes 16 %, band cells 7 %, segments
13 %, eosinophils 6 %, basophils 2 %, monocytes 21 %,
lymphocytes 47 %). Evaluation of peripheral blood
smear revealed the presence of neutrophils with features
of dysplasia (asynchronous maturation of the nucleus and
the cytoplasm, low nuclear–cytoplasmic ratio, and abun-
dant azurophilic grains with co-existing visible conden-
sations of nuclear chromatin at all stages of develop-
ment). The number of lobes in mature neutrophils did
not exceed three; however, in some of the neutrophils
nuclear constriction was not apparent (Fig. 1). Taking
into account the long-term immunosuppressive therapy
and the increase in the number of immature granulocytes,
we decided to establish the differential diagnosis between
a myeloproliferative disorder and a reactive process.
Reverse transcription-PCR did not detect any BCR-
ABL (p210) rearrangement. Bone marrow examination
did not confirm the presence of a neoplastic transforma-
tion. Virological tests detecting cytomegalovirus and
Epstein–Barr virus infection were negative. Owing to
the above-mentioned results, we began to suspect that
the observed dysgranulopoiesis was associated with the
immunosuppressive therapy. In accordance with this sus-
picion, MMF was withdrawn, which resulted in an im-
mediate normalization of granulocyte morphology and
count. During further treatment with prednisone, a deple-
tion of B-lymphocytes was maintained and the 12-year-
old boy remained in clinical remission. At the 6-month
follow-up we observed an increase in the number of
CD20 lymphocytes, which coincided with a relapse of
the nephrotic syndrome and symptoms of steroid toxicity
and high-dose steroid-dependency.
Questions
1. What is the final diagnosis of the disorder that was respon-
sible for the neutrophil dysplasia?
2. What does Fig. 1 show?
3. What further treatment may have been effective in the
patient?
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Fig. 1 Peripheral blood smear
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